

Fiscal Note 2023 Biennium

Bill # S	B0137		Title:	1	ing requirements for on drug costs	transparency in
Primary Sponsor: F	itzpatrick, Steve		Status:	As Introd	uced	
☐Significant Local Gov Impact		⊠Needs to be included in HB 2 □ Technical Concerns				
☐ Included in the Executive Budget		☐ Significant Long-Term Impacts ☐ Dedicated Revenue Form Attached				
		EISCAI SII	NANA AD	X 7		-
		FISCAL SUMMARY FY 2022 FY 2023 FY 2024 FY 2025				FY 2025
		Difference	Diffe		Difference	Difference
Expenditures:						
General Fund		\$0		\$0	\$0	\$0
State Special Revenue		\$57,862	\$	547,462	\$48,076	\$48,797
Revenue:						
General Fund		\$0		\$0	\$0	\$0
State Special Rever	nue	\$0		\$0	\$0	\$0
Net Impact-General	l Fund Balance:	\$0		\$0	\$0	\$0

<u>Description of fiscal impact:</u> This bill creates the Montana Prescription Drug Transparency Act, requiring the Commissioner of Securities and Insurance to develop a website, adopt rules, and assess a penalty.

FISCAL ANALYSIS

Assumptions:

State Auditor's Office

- 1. The Commissioner of Securities and Insurance (CSI) will contract to develop a website to include pharmaceutical drug manufacturer (PDM) reports. The cost to contract is estimated at \$7,000 in FY 2022.
- 2. The CSI may adopt rules necessary to implement the requirements of the bill. The cost of the rules adoption is expected to be \$600 in FY 2022.
- 3. The CSI shall ensure the timely submission of the various reports required by the bill and will review these reports to ensure they retain the information required by the bill as well as information subsequently identified by rulemaking.
- 4. To administer these ongoing duties and responsibilities, a 0.50 FTE Program Specialist will be hired. Total personal services costs for salaries and benefits are estimated to be \$39,962 in FY 2022 and 2023, \$40,463 in FY 2024, and \$41,070 in FY 2025.

- 5. Operating costs related to the 0.50 FTE Program Specialist include rent, phone, and miscellaneous charges. For FY 2022, a one-time office package (\$1,600) and computer costs (\$1,200) are also included. Costs are estimated at \$10,300 in FY 2022, \$7,500 in FY 2023, \$7,613 in FY 2024, and \$7,727 in FY 2025.
- 6. Personal services and operating costs include an inflationary adjustment of 1.5% in FY 2024 and 2025.
- 7. The CSI shall assess a penalty against a PDM for non-compliance with the provisions of the bill. The amount of revenue resulting from potential penalties is not estimable.
- 8. Any potential penalties must be used to offset the costs of administering the requirements of this bill.
- 9. Any money from assessed penalties remaining, after paying for the costs of administering the bill, must be deposited in the general fund.

Department of Labor and Industry

10. There is no impact to the Department of Labor and Industry from SB 137, since the department will continue to administer the Montana Prescription Drug Registry, which is a separate database.

	FY 2022 Difference	FY 2023 Difference	FY 2024 Difference	FY 2025 Difference						
Fiscal Impact:			<u>Dimerence</u>	Difference						
FTE	0.50	0.50	0.50	0.50						
Expenditures:										
Personal Services	\$39,962	\$39,962	\$40,463	\$41,070						
Operating Expenses	\$17,900	\$7,500	\$7,613	\$7,727						
TOTAL Expenditures	\$57,862	\$47,462	\$48,076	\$48,797						
Funding of Expenditures:										
General Fund (01)	\$0	\$0	\$0	\$0						
State Special Revenue (02)	\$57,862	\$47,462	\$48,076	\$48,797						
TOTAL Funding of Exp.	\$57,862	\$47,462	\$48,076	\$48,797						
Revenues:										
General Fund (01)	\$0	\$0	\$0	\$0						
State Special Revenue (02)	\$0	\$0	\$0	\$0						
TOTAL Revenues	\$0	\$0	\$0	\$0						
Net Impact to Fund Balance (Revenue minus Funding of Expenditures):										
General Fund (01)	\$0	\$0	\$0	\$0						
State Special Revenue (02)	(\$57,862)	(\$47,462)	(\$48,076)	(\$48,797)						

NO SPONSOR SIGNATURE	1/29/21	KA	3/20/21
Sponsor's Initials	Date	Budget Director's Initials	Date